Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of NNC6019-0001 at Two Dose Levels in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR CM)

NCT05442047 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05442047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05442047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of NNC6019-0001 at Two Dose Levels in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
August 2, 2022
Completion date
May 13, 2025
Enrollment
105 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin amyloid cardiomyopathy (attr cm)